Patents by Inventor Rachel HAMRI

Rachel HAMRI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVE
    Publication number: 20220202838
    Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter”Bchl-D) for use in combination therapy for cancer. wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
    Type: Application
    Filed: March 21, 2022
    Publication date: June 30, 2022
    Inventors: Avigdor SCHERZ, Yoram SALOMON, Lilach AGEMY, Rachel HAMRI, Dina PREISE, Kwanghee KIM, Jonathan COLEMAN
  • Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
    Patent number: 11278555
    Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: March 22, 2022
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Avigdor Scherz, Yoram Salomon, Lilach Agemy, Rachel Hamri, Dina Preise, Kwanghee Kim, Jonathan Coleman
  • COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVE
    Publication number: 20190125769
    Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
    Type: Application
    Filed: April 10, 2017
    Publication date: May 2, 2019
    Inventors: Avigdor SCHERZ, Yoram SALOMON, LiIach AGEMY, Rachel HAMRI, Dina PREISE, Kwanghee KIM, Jonathan COLEMAN